New insider activity at Arcutis Biotherapeutics ( (ARQT) ) has taken place on April 4, 2025.
CFO David Joseph Topper has recently sold 9,600 shares of Arcutis Biotherapeutics stock, totaling a transaction value of $151,680.
Recent Updates on ARQT stock
Recent developments for Arcutis Biotherapeutics have been positive, with significant news impacting its stock. The company reached a joint stipulation agreement with Padagis to stay ongoing patent litigation, which is seen as a strategic win, enhancing the exclusivity and strategic value of Arcutis shares. This move is expected to provide greater confidence to potential acquirers about the extended exclusivity period. Additionally, Jefferies raised its price target for Arcutis, citing the company’s steady growth in Zoryve prescriptions and consistent quarterly performance. The firm also noted that Arcutis is benefiting from a market shift towards commercial biotech names, which has lowered the risk profile. Furthermore, Arcutis announced new positive data from clinical trials, showcasing the efficacy and tolerability of its ZORYVE cream and foam, which further supports its market expansion and growth prospects.
More about Arcutis Biotherapeutics
YTD Price Performance: 14.01%
Average Trading Volume: 2,393,334
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.78B